Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A H Calvert

Showing results (71-80 of 148) with videos related to

Pageof 15
Sort By:
Journal of Medicinal Chemistry|September 30, 1994
The synthesis and thymidylate synthase inhibitory activity of L-gamma-L-linked dipeptide and L-gamma-amide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)G M Bisset, V Bavetsias, T J Thornton, et al.
Lancet (London, England)|May 3, 1986
Phase II trials in metastatic bladder cancerR R Hall, A H Calvert, B De Stavola, et al.
British Journal of Cancer|January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancerN Siddiqui, A V Boddy, H D Thomas, et al.
Advances in Enzyme Regulation|January 1, 1991
Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolatesA L Jackman, P R Marsham, R G Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1988
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancerB M Cantwell, V Macaulay, A L Harris, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
European Journal of Cancer|May 1, 1980
Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistanceA H Calvert, T R Jones, P J Dady, et al.
Pageof 15

Showing results (71-80 of 148) with videos related to

Sort By:
Pageof 15
Journal of Medicinal Chemistry|September 30, 1994
The synthesis and thymidylate synthase inhibitory activity of L-gamma-L-linked dipeptide and L-gamma-amide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)G M Bisset, V Bavetsias, T J Thornton, et al.
Lancet (London, England)|May 3, 1986
Phase II trials in metastatic bladder cancerR R Hall, A H Calvert, B De Stavola, et al.
British Journal of Cancer|January 1, 1997
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancerN Siddiqui, A V Boddy, H D Thomas, et al.
Advances in Enzyme Regulation|January 1, 1991
Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolatesA L Jackman, P R Marsham, R G Moran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitroE Marshman, D R Newell, A H Calvert, et al.
European Journal of Cancer & Clinical Oncology|April 1, 1988
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancerB M Cantwell, V Macaulay, A L Harris, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)D L Alison, D R Newell, C Sessa, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2002
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)M A Batey, J G Wright, A Azzabi, et al.
British Journal of Cancer|November 1, 1991
The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in miceD I Jodrell, D R Newell, S E Morgan, et al.
European Journal of Cancer|May 1, 1980
Quinazoline antifolates with dual biochemical loci of action. Biochemical and biological studies directed towards overcoming methotrexate resistanceA H Calvert, T R Jones, P J Dady, et al.
Pageof 15